Here’s a detailed and polished version of the BCR-ABL (CML, AML, ALL) test information — ideal for brochures, doctor reference guides, or lab catalogs:

Test Name:

BCR-ABL (CML, AML, ALL)
(Philadelphia Chromosome / t(9;22)(q34;q11) Detection)

Clinical Significance:

The BCR-ABL fusion gene results from the Philadelphia chromosome translocation t(9;22) and leads to the production of a constitutively active tyrosine kinase, which drives malignant cell proliferation. It is associated with:

• Chronic Myeloid Leukemia (CML): Found in >95% of cases

• Acute Lymphoblastic Leukemia (ALL): Especially adult B-ALL (~25–30%)

• Acute Myeloid Leukemia (AML): Rare but can be present in certain subtypes

Sample Requirements:

• Sample Type: Peripheral Blood / Bone Marrow

• Collection Tube: EDTA or Sodium Heparin Vacutainer

• Volume: 2–3 mL

• Transport Conditions: Room temperature; avoid freezing

Methodology:

• Real-Time PCR (qRT-PCR) – For detection and quantification

• FISH (Fluorescence In Situ Hybridization) – For initial diagnosis

• Qualitative RT-PCR or Quantitative RT-PCR (as applicable)

Turnaround Time:

3-7 working days

Indications for Testing:

• Diagnosis of CML, ALL, or AML

• Baseline molecular profiling

• Monitoring treatment response in CML (TKI therapy)

• Minimal Residual Disease (MRD) monitoring

• Detection of resistance or disease progression

Interpretation:

• Positive Result: Confirms presence of BCR-ABL1 fusion — suggests CML, Ph+ ALL, or rare Ph+ AML

• Quantitative Results (for CML): Track BCR-ABL transcript levels over time to assess response to therapy

• Negative Result: No BCR-ABL fusion detected